Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*

(Incorporated in Israel with limited liability)

(Stock Code: 1696)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Sisram Medical Ltd (the "**Company**") on a voluntary basis.

The Company is aware that the market continues to pay attention to the commercialization progress of RT002 in Mainland China, with the trademark of 达希斐® in Mainland China and the English trademark of DAXXIFY® (DaxibotulinumtoxinA-lanm, the "**Product**").

The Company hereby clarifies that, as of the date of this announcement, the commercialization of the Product in Mainland China is proceeding steadily. Preparation work relating to regulatory filings, market access, and the buildout of a professional team are being carried out in an orderly manner. The Company maintains strong confidence in the application prospects of the Product in the Chinese market and will make further disclosures as appropriate based on the actual developments.

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, July 28, 2025

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Jiahong LI as Executive Directors; Mr. Yifang WU and Ms. Rongli FENG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non- executive Directors.

* *for identification purpose only*